[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prof. Franciszek Lukaszczyk Memorial Oncology Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100643886","ttfields-plus-fet-pet-guided-stereotactic-radiosurgery-versus-ttfields-alone-for-recurrent-glioblastoma-tarrget-20-100643886",false,"NCT07668869","TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)","Tumor Treating Fields (TTFields) Concomitant With Stereotactic Radiosurgery Based on FET-PET vs TTFields Alone for the Treatment of Recurrent, Glioblastoma (Tarrget 2.0)","Inclusion Criteria:\n\n* Age ≥18 years\n* Karnofsky Performance Status ≥70\n* Histologically confirmed IDH-wildtype glioblastoma\n* First, second, or third recurrence\n* Radiological recurrence according to RANO 2.0 criteria\n* Prior radiotherapy and temozolomide treatment\n* At least 6 months since completion of previous radiotherapy\n* Contrast-enhancing recurrent lesion visible on MRI\n* Maximum recurrent lesion diameter ≤5 cm\n* Available molecular profile including IDH and MGMT status\n* Adequate hematologic, renal, and hepatic function\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous bevacizumab treatment\n* Planned chemotherapy or targeted therapy after study intervention\n* Previous stereotactic re-irradiation within the planned treatment field\n* More than three recurrences\n* Significant psychiatric disorders\n* Significant unrelated neurological disease\n* Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device\n* Pregnancy or breastfeeding\n* Active intracranial hemorrhage\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* Participation in another interventional study likely to interfere with this study","ALL","18 Years",{"count":19,"type":20},92,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.\n\nPatients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation.\n\nThe study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.",[26,27,28],"Glioblastoma","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Glioblastoma Multiforme, Adult",[30],"glioblastoma, TTF, SRS, radiosurgery, stereotactic radiotherapy","RECRUITING","2026-06-19",{"date":34,"type":35},"2026-06-25","ACTUAL",{"date":37,"type":35},"2025-12-30",{"date":39,"type":20},"2032-06",{"name":41,"class":42},"Prof. Franciszek Lukaszczyk Memorial Oncology Center","OTHER",""]